Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Crystal Zheng, Indrani Kar, Claire Kaori Chen, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 879-896
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 345
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
Mahsa Khayat-Khoei, Shamik Bhattacharyya, Joshua Katz, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1093-1106
Open Access | Times Cited: 116
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder, Diego Centonze, Maria L. Naylor, et al.
CNS Drugs (2021) Vol. 35, Iss. 3, pp. 317-330
Open Access | Times Cited: 112
COVID-19 in ocrelizumab-treated people with multiple sclerosis
Richard A. Hughes, L Whitley, Kocho Fitovski, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 49, pp. 102725-102725
Open Access | Times Cited: 77
Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Hannah Kelly, Brent S. Sokola, Hesham Abboud
Journal of Neuroimmunology (2021) Vol. 356, pp. 577599-577599
Open Access | Times Cited: 72
Administration of COVID-19 vaccines in immunocompromised patients
Manica Negahdaripour, Mojtaba Shafiekhani, Seyed Mohammad Iman Moezzi, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108021-108021
Open Access | Times Cited: 72
Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic
Saikat Dewanjee, V. Jayalakshmi, Rajkumar Singh Kalra, et al.
Molecular Neurobiology (2021) Vol. 58, Iss. 9, pp. 4694-4715
Open Access | Times Cited: 64
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 51
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Gavin Giovannoni, Joela Mathews
Neurology and Therapy (2022) Vol. 11, Iss. 2, pp. 571-595
Open Access | Times Cited: 39
Demyelination as a result of an immune response in patients with COVID-19
Zahra Shabani
Acta Neurologica Belgica (2021) Vol. 121, Iss. 4, pp. 859-866
Open Access | Times Cited: 50
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Carmen Tur, Anne‐Laure Dubessy, Susana Otero‐Romero, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 9, pp. 1424-1456
Open Access | Times Cited: 33
A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases
Zahra Hamidi, Shaghaiegh Jabraeili-Siahroud, Yalda Taati-Alamdari, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 20
Ocrelizumab Impairs the Phenotype and Function of Memory CD8 + T Cells
Amandine Mathias, Vasiliki Pantazou, Sylvain Perriot, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 2
Open Access | Times Cited: 18
COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment
Shaghayegh Sadeghmousavi, Nima Rezaei
SN Comprehensive Clinical Medicine (2020) Vol. 2, Iss. 10, pp. 1802-1807
Open Access | Times Cited: 43
Knowledge domain and trend of disease-modifying therapies for multiple sclerosis: A study based on CiteSpace
Ting Zheng, Taotao Jiang, Zilong Huang, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26173-e26173
Open Access | Times Cited: 4
Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic
Hind Alnajashi, Razan Jabbad
PLoS ONE (2020) Vol. 15, Iss. 10, pp. e0241103-e0241103
Open Access | Times Cited: 38
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Johann Sellner, Paulus Rommer
Vaccines (2021) Vol. 9, Iss. 2, pp. 99-99
Open Access | Times Cited: 27
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society
Monika Nojszewska, Alicja Kalinowska-Łyszczarz, Monika Adamczyk‐Sowa, et al.
Neurologia i Neurochirurgia Polska (2021) Vol. 55, Iss. 1, pp. 8-11
Open Access | Times Cited: 27
Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis
Katja Burian, Felicita Heidler, Niklas Frahm, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies
Saurabh Kataria, Medha Tandon, Violina Melnic, et al.
eNeurologicalSci (2020) Vol. 21, pp. 100287-100287
Open Access | Times Cited: 28
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Marzia Fronza, Lorena Lorefice, Jessica Frau, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 1993-2004
Open Access | Times Cited: 25
Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist
Alexandra Galati, E. Sherwood Brown, Riley Bove, et al.
Journal of the Neurological Sciences (2021) Vol. 430, pp. 120004-120004
Closed Access | Times Cited: 23
Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
Gabriel Bsteh, Harald Hegen, Gerhard Traxler, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 5, pp. 1538-1544
Open Access | Times Cited: 16
Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis
Chao-Yang Chen, Enyao Zhang, Chunsu Zhu, et al.
Journal of the American Pharmacists Association (2022) Vol. 63, Iss. 1, pp. 8-22.e23
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top